European House Dust Mite (Der p 5) IgE Test · Blood

If you have ongoing nasal symptoms, wheeze, or stubborn eczema and a standard dust mite test came back positive, you still do not know the whole story. The mite is not one allergen; it carries dozens of proteins, and your immune system may react to some but not others. The pattern of which ones you react to predicts how severe your disease can get.

This test measures IgE (immunoglobulin E, the antibody behind allergic reactions) against Der p 5, a specific protein from the European house dust mite. People who react to Der p 5, especially alongside other mite proteins, tend to have asthma or atopic dermatitis rather than just simple hay fever, and they often run a more complex course of disease.

What This Test Actually Measures

The lab is looking at blood for one specific antibody: IgE that recognizes Der p 5 (a protein produced by Dermatophagoides pteronyssinus, the European house dust mite). This is a component-resolved test, meaning it zooms in on a single molecule rather than the whole mite extract that older tests use.

This is what allergists call a mid-tier or minor allergen. The classic major mite allergens are Der p 1, Der p 2, and Der p 23, which capture the majority of people with dust mite allergy. Der p 5 sits one layer below those, recognized by a smaller but clinically meaningful slice of allergic people. In population studies, roughly 15 to 30 percent of mite-sensitized adults have IgE against Der p 5; in people with atopic dermatitis under heavy mite exposure, that figure can climb above 65 percent.

Why Der p 5 IgE Matters for Asthma

The most consistent signal in the research is that Der p 5 reactivity tracks with the lower airway, not just the nose. Asthmatic children with mite allergy have higher Der p 5 IgE levels and recognize more mite proteins overall than children who are sensitized but do not have asthma. Reactions to Der p 5 and a related protein, Der p 21, are more common in allergic asthma than in isolated rhinitis.

In a study of 384 mite-allergic patients, the more mite components a person reacted to, the more likely they were to have asthma or atopic dermatitis instead of nasal symptoms alone. Der p 5, Der p 20, and Der p 21 stood out as the components most tied to severity. If your standard mite test is positive and you also have wheeze, this layer of detail can help explain why.

Why Der p 5 IgE Matters for Atopic Dermatitis

Severe atopic dermatitis (the chronic, itchy, inflamed skin condition) often runs alongside broad mite sensitization. In studies of patients with type 2 high atopic dermatitis (a form driven by a specific allergic immune pathway), Der p 5 IgE was detectable in roughly two thirds of patients, and adding Der p 5 to a component panel along with Der p 1, 2, 7, 21, and 23 identified over 97 percent of mite-allergic atopic dermatitis cases.

Translation for you: if your eczema is moderate to severe and conventional treatment is not holding it, knowing whether you carry a broad, mid-tier mite sensitization pattern (including Der p 5) helps explain the underlying immune driver and may shape how aggressively to pursue mite-directed treatment.

What a Positive Result Suggests About Disease Complexity

A positive Der p 5 IgE rarely shows up alone. It typically appears alongside IgE to several other mite proteins, marking what researchers call polysensitization. People with polysensitized profiles that include Der p 5 generally have more symptomatic, multi-organ allergic disease (nose, lungs, skin) than people sensitized only to Der p 1 and Der p 2.

A negative Der p 5 result does not rule out mite allergy. Many people are sensitized only to the major components, Der p 1, 2, and 23, and they can still have significant disease. A simpler sensitization profile, however, sometimes responds particularly well to standard mite allergen immunotherapy, the long-term treatment that retrains your immune system away from the allergen.

How This Test Relates to Immunotherapy

Allergen immunotherapy (SCIT for shots, SLIT for sublingual tablets) is the closest thing to a root-cause treatment for mite allergy. Standard mite immunotherapy products are built primarily around Der p 1 and Der p 2 and produce strong protective antibody responses against those proteins. The same products do not generate as much protective response against Der p 5, Der p 7, or Der p 21, and treatment outcomes are often less reliable in people whose IgE reactivity reaches beyond Der p 1 and Der p 2.

There is a flip side. In Chinese allergic rhinitis cohorts, patients who already had IgE to minor components like Der p 5, 7, and 21 before starting subcutaneous immunotherapy actually showed greater symptom improvement on treatment, while patients who lacked these antibodies sometimes developed them during therapy. Knowing your Der p 5 status before starting immunotherapy gives you a more informed baseline to track against.

Reconciling the Contradictory Findings

Two facts from the research seem to point in opposite directions. Der p 5 sensitization marks more severe, more complex disease, yet patients with Der p 5 IgE can respond better to immunotherapy. This is not actually a paradox. Der p 5 is a phenotype indicator, not a good or bad number. It tells you what kind of allergic system you have, and different phenotypes respond differently to different treatments. A standard mite vaccine may underperform because it does not contain enough Der p 5 protein to retrain that arm of the response, but the person's immune system may still be more amenable to immunotherapy overall because of how broadly engaged it is.

How Biologic Drugs Affect This Number

In real-world data from adults with severe atopic dermatitis, dupilumab (a biologic medication that blocks the IL-4 and IL-13 signaling pathways central to allergic inflammation) significantly reduced serum IgE against multiple mite components, including Der p 5, Der p 7, Der p 21, and Der p 23, over 52 weeks of treatment. If you are on dupilumab or considering it, this test can serve as one objective marker of how deeply the medication is dampening your allergic system.

Why a Single Reading Is Not Enough

Allergen-specific IgE levels are not perfectly stable. They drift with seasonal exposure, intercurrent illness, recent allergen contact, and the early phases of treatment. The trajectory of your number over time tells a richer story than any single result. If you start mite immunotherapy or a biologic, the value of testing is in watching whether your Der p 5 IgE trends down across months and years, not in any one snapshot.

Get a baseline before starting any new mite-directed treatment. If you are changing your home environment, starting immunotherapy, or starting a biologic, retest at 6 to 12 months and at least annually afterward. If symptoms shift unexpectedly, retest sooner.

When Results Can Be Misleading

• Recent heavy allergen exposure: a major mite-rich exposure in the days before testing (a dusty move, deep cleaning, sleeping in mite-heavy bedding) can transiently lift specific IgE levels above your usual baseline.
• Active allergic disease: drawing blood during a severe asthma flare or eczema exacerbation can produce a higher reading than your stable state.
• Recent biologic dose timing: if you are on omalizumab, dupilumab, or another biologic that lowers IgE, the timing of your last dose relative to the blood draw can shift the result, and the underlying allergic biology may not have fully changed yet.
• Test platform differences: Der p 5 is a component test offered by some labs but not others, and methods are not fully standardized across platforms, so two labs may give modestly different numbers for the same sample.

What to Do With an Out-of-Pattern Result

If Der p 5 IgE comes back positive, the next step depends on the picture as a whole. Pair this result with the major mite components (Der p 1, Der p 2, Der p 23) and with your symptom profile. A broad positive panel that includes Der p 5 plus asthma or moderate-to-severe eczema is a strong indication to work with an allergist on a structured plan, which may include serious mite avoidance measures, allergen immunotherapy, or a biologic. A negative Der p 5 result paired with positive Der p 1 and Der p 2 typically points to a simpler phenotype that is more likely to respond cleanly to standard mite immunotherapy.

This test is not a substitute for the skin prick test or nasal provocation testing your allergist may run to confirm clinically relevant allergy. It is best used in combination with those, and with total IgE, to map out your specific allergic signature.